ICM
KLRS

Irenic Capital Management’s Kalaris Therapeutics KLRS Stock Holding History

Irenic Capital Management’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-112,156
Closed -$1.95M – 26
2024
Q1 		$1.95M Buy
+112,156
New +$1.83M 0.4% 18

Other funds holding KLRS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AI
Acuitas Investments Seattle, Washington $1.41M AUM 48.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Irenic Capital Management's KLRS Position: Q2 2024 in Review

Irenic Capital Management sold out of Kalaris Therapeutics (KLRS) in Q2 2024, closing a stake of 112,156 shares — an estimated $1.95M sold.

Irenic Capital Management first reported a position in KLRS in Q1 2024 and held it in 1 quarter. The position peaked at $1.95M in Q1 2024. 71 funds tracked by Wall St. Rank hold KLRS as of Q2 2024.

  • Irenic Capital Management reported no remaining Kalaris Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Irenic Capital Management sold 112,156 Kalaris Therapeutics shares in Q2 2024, an estimated $1.95M.
  • Irenic Capital Management first reported a position in Kalaris Therapeutics in Q1 2024 and held it in 1 quarter.
  • Irenic Capital Management's Kalaris Therapeutics position peaked at $1.95M in Q1 2024.
  • 71 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2024.

Based on Irenic Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.